Furthermore, in recent years, chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has demonstrated rapid and profound responses in treating MM/RRMM. Here, TNFRSF17 is linked to Miyoshi myopathy.